Abstract GS2-02: Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis

S. Sinha, L. Panebianco, X. Wu, Dongliang Wang, Danning Huang, A. Sivapiragasam
{"title":"Abstract GS2-02: Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis","authors":"S. Sinha, L. Panebianco, X. Wu, Dongliang Wang, Danning Huang, A. Sivapiragasam","doi":"10.1158/1538-7445.SABCS18-GS2-02","DOIUrl":null,"url":null,"abstract":"Background: The role of adjuvant chemotherapy in early stage breast cancer is well established with survival benefit seen in long term follow up studies, but only a small minority of patients in these studies were >65 years old. Dose and schedule can be tailored according to the special requirements of an elderly patient, as stated by the International Society of Geriatric Oncology (SIOG). However the magnitude of the benefit and trends in utilization of adjuvant chemotherapy has not been well studied in this population. Methods: Female patients above 65 years age with stage I to III breast cancer were identified from the NCDB database from 2004-2015. Factors predicting utility of chemotherapy were assessed with multivariate analysis. Kaplan Meier curves were constructed for calculation of overall survival (OS) with hazard ratio (HR) estimated from cox model. Log rank test and pearson chi square was used for comparison between groups. Groups were compared for OS benefit at 5 and 10 years. Results: Of a total of 2,445,730 patients analyzed, 160,676 met our inclusion criteria. Of them, 21,743 were >80 years old. Factors predicting use of adjuvant chemotherapy were shown in table 1. OS benefit was seen in patients who received adjuvant chemotherapy regardless of their age, ER, PR, HER-2 status or stage. Patients with TNBC had an HR of 0.547. More benefit was seen in the higher stages. HR for stages I, II, and III were 0.801, 0.608, and 0.666 respectively. Conclusions: Adjuvant chemotherapy is considered standard of care for patients with early stage breast cancer. Elderly patients are more likely to get adjuvant chemotherapy based on histology, age Citation Format: Sinha S, Panebianco L, Wu X, Wang D, Huang D, Sivapiragasam A. Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS2-02.","PeriodicalId":12697,"journal":{"name":"General Session Abstracts","volume":"124 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General Session Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.SABCS18-GS2-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: The role of adjuvant chemotherapy in early stage breast cancer is well established with survival benefit seen in long term follow up studies, but only a small minority of patients in these studies were >65 years old. Dose and schedule can be tailored according to the special requirements of an elderly patient, as stated by the International Society of Geriatric Oncology (SIOG). However the magnitude of the benefit and trends in utilization of adjuvant chemotherapy has not been well studied in this population. Methods: Female patients above 65 years age with stage I to III breast cancer were identified from the NCDB database from 2004-2015. Factors predicting utility of chemotherapy were assessed with multivariate analysis. Kaplan Meier curves were constructed for calculation of overall survival (OS) with hazard ratio (HR) estimated from cox model. Log rank test and pearson chi square was used for comparison between groups. Groups were compared for OS benefit at 5 and 10 years. Results: Of a total of 2,445,730 patients analyzed, 160,676 met our inclusion criteria. Of them, 21,743 were >80 years old. Factors predicting use of adjuvant chemotherapy were shown in table 1. OS benefit was seen in patients who received adjuvant chemotherapy regardless of their age, ER, PR, HER-2 status or stage. Patients with TNBC had an HR of 0.547. More benefit was seen in the higher stages. HR for stages I, II, and III were 0.801, 0.608, and 0.666 respectively. Conclusions: Adjuvant chemotherapy is considered standard of care for patients with early stage breast cancer. Elderly patients are more likely to get adjuvant chemotherapy based on histology, age Citation Format: Sinha S, Panebianco L, Wu X, Wang D, Huang D, Sivapiragasam A. Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS2-02.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
GS2-02:老年人群I、II、III期乳腺癌辅助化疗的疗效和使用趋势:国家癌症数据库(NCDB)分析
背景:在长期随访研究中,辅助化疗在早期乳腺癌中的作用已经得到了很好的确立,并能带来生存益处,但在这些研究中,只有一小部分患者的年龄大于65岁。根据国际老年肿瘤学会(International Society of Geriatric Oncology, SIOG)的规定,剂量和时间表可以根据老年患者的特殊要求进行调整。然而,在这一人群中,辅助化疗的获益程度和使用趋势尚未得到很好的研究。方法:从2004-2015年NCDB数据库中确定65岁以上的1至3期女性乳腺癌患者。预测化疗效用的因素通过多变量分析进行评估。构建Kaplan Meier曲线计算总生存期(OS),并根据cox模型估算风险比(HR)。组间比较采用对数秩检验和皮尔逊卡方。比较各组在5年和10年的OS获益。结果:在分析的2,445,730例患者中,160,676例符合我们的纳入标准。其中,年龄>80岁的有21743人。预测辅助化疗使用的因素见表1。无论年龄、ER、PR、HER-2状态或分期如何,接受辅助化疗的患者均可获得OS益处。TNBC患者的HR为0.547。在较高的阶段可以看到更多的益处。I期、II期和III期的HR分别为0.801、0.608和0.666。结论:辅助化疗被认为是早期乳腺癌患者的标准治疗。基于组织学、年龄的老年患者更容易接受辅助化疗。引用格式:Sinha S, Panebianco L, Wu X, Wang D, Huang D, Sivapiragasam A.老年人群I、II、III期乳腺癌辅助化疗疗效及利用趋势:A National cancer Database (NCDB)分析[摘要]。2018年圣安东尼奥乳腺癌研讨会论文集;2018年12月4-8日;费城(PA): AACR;癌症杂志,2019;79(4增刊):摘要nr GS2-02。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group Abstract GS3-07: Identifying patients whose symptoms are under-recognized during breast radiotherapy: Comparison of patient and physician reports of toxicity in a multicenter cohort Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients Abstract GS5-01: A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab Abstract GS4-02: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1